Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy GeoVax Labs stock

Learn how to easily invest in GeoVax Labs stock.

GeoVax Labs Inc is a biotechnology business based in the US. GeoVax Labs shares (GOVX) are listed on the NASDAQ and all prices are listed in US Dollars. GeoVax Labs employs 11 staff and has a trailing 12-month revenue of around $276,902.

How to buy shares in GeoVax Labs

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GOVX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

GeoVax Labs stock price (NASDAQ: GOVX)

Use our graph to track the performance of GOVX stocks over time.

GeoVax Labs shares at a glance

Information last updated 2022-09-25.
Latest market close$1.08
52-week range$0.55 - $5.61
50-day moving average $1.72
200-day moving average $1.81
Wall St. target price$6.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.97

Buy GeoVax Labs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy GeoVax Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GeoVax Labs price performance over time

Historical closes compared with the close of $1.08 from 2022-09-27

1 week (2022-09-22) 8.36%
1 month (2022-08-29) -10.74%
3 months (2022-06-29) 26.32%
6 months (2022-03-29) -18.80%
1 year (2021-09-29) -76.00%
2 years (2020-09-29) -63.27%
3 years (2019-09-27) 13,400.00%
5 years (2017-09-29) 2,600.00%

GeoVax Labs financials

Revenue TTM $276,902
Gross profit TTM $-15,168,670
Return on assets TTM -47.98%
Return on equity TTM -86.04%
Profit margin 0%
Book value $1.72
Market capitalisation $28.5 million

TTM: trailing 12 months

GeoVax Labs share dividends

We're not expecting GeoVax Labs to pay a dividend over the next 12 months.

You may also wish to consider:

Have GeoVax Labs's shares ever split?

GeoVax Labs's shares were split on a 1:20 basis on 25 September 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GeoVax Labs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for GeoVax Labs shares which in turn could have impacted GeoVax Labs's share price.

GeoVax Labs share price volatility

Over the last 12 months, GeoVax Labs's shares have ranged in value from as little as $0.5495 up to $5.61. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GeoVax Labs's is 3.306. This would suggest that GeoVax Labs's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put GeoVax Labs's beta into context you can compare it against those of similar companies.

GeoVax Labs overview

GeoVax Labs, Inc. , a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U. S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc.

Frequently asked questions

What percentage of GeoVax Labs is owned by insiders or institutions?
Currently 1.162% of GeoVax Labs shares are held by insiders and 10.254% by institutions.
How many people work for GeoVax Labs?
Latest data suggests 11 work at GeoVax Labs.
When does the fiscal year end for GeoVax Labs?
GeoVax Labs's fiscal year ends in December.
Where is GeoVax Labs based?
GeoVax Labs's address is: 1900 Lake Park Drive, Smyrna, GA, United States, 30080
What is GeoVax Labs's ISIN number?
GeoVax Labs's international securities identification number is: US3736785078
What is GeoVax Labs's CUSIP number?
GeoVax Labs's Committee on Uniform Securities Identification Procedures number is: 238326102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site